MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202521015488 A) filed by Rungta International Skills University; Rungta College Of Engineering & Technology; and Rungta College Of Pharmaceutical Sciences And Research on February 22, 2025, for Precision Crispr-Cas9 Delivery System For Autoimmune Skin Conditions Using Microneedle Patches.
Inventors include Aachal Lonhare; Shabnam Nisha; Asha Manikpuri; Dr. Neetu Shrivastava; Dr. Shikha Shrivastava; and Anushka Chakraborty.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: Precision CRISPR-Cas9 Delivery System for Autoimmune Skin Conditions Using Microneedle Patches This invention describes an innovative non-invasive gene- editing system designed specifically for the treatment of autoimmune skin conditions, such as psoriasis. Utilizing CRISPR-Cas9 technology, the system incorporates biodegradable microneedle patches that deliver therapeutic agents directly to affected dermal cells. An integral component of this system is the advanced artificial intelligence (AI) module that dynamically analyzes real-time biosensor feedback to adjust gene-editing protocols based on inflammatory marker data. This adaptive approach ensures precision in the delivery and efficacy of the treatment, enhancing patient outcomes. The system is designed for at-home use, offering a user-friendly interface that promotes consistent adherence to treatment protocols. This abstract encapsulates the system's ability to combine cutting-edge genetic technology and smart diagnostics to provide a targeted, effective, and patient-centric solution for managing autoimmune skin disorders.
Disclaimer: Curated by HT Syndication.
